Ligand Pharmaceuticals stock hits 52-week high at $172.49

Published 29/09/2025, 15:50
Ligand Pharmaceuticals stock hits 52-week high at $172.49

Ligand Pharmaceuticals Incorporated stock reached a 52-week high, hitting $172.49. This milestone reflects a significant upward trajectory for the company over the past year, with analysts setting price targets ranging from $164 to $206. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 5.45, indicating robust liquidity. The stock has seen a remarkable 71.54% increase in its value over the last 12 months, underscoring investor confidence and positive market sentiment. With revenue growth of 40.54% and analysts expecting profitability this year, Ligand Pharmaceuticals, a company known for its innovative approaches in drug discovery and development, has continued to capture the attention of market participants. InvestingPro subscribers can access 10+ additional investment tips and comprehensive analysis in the Pro Research Report, essential for understanding the complete investment picture.

In other recent news, Ligand Pharmaceuticals has completed a significant financial maneuver by raising $460 million through a convertible notes offering, with net proceeds amounting to approximately $445.1 million after deducting fees and expenses. This capital raise has influenced several analysts to adjust their price targets for the company. Oppenheimer increased its price target to $190, citing the successful mid-August capital raise and maintaining an Outperform rating. Similarly, Benchmark raised its price target to $175, highlighting Ligand’s strong second-quarter 2025 earnings report as a key factor. H.C. Wainwright also raised its price target to $206, following the FDA’s approval of an update to the REMS labeling for FILSPARI, which included reduced liver function monitoring and the removal of pregnancy monitoring requirements. These developments reflect a positive outlook from analysts regarding Ligand’s recent financial and regulatory achievements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.